These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 33248314

  • 1. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y, Grant MS, Zhang X, Paraghamian SE, Tan X, Clark LH.
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [Abstract] [Full Text] [Related]

  • 2. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF, Zhang GN, Peng CR, Shi Y, Shi XW.
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun 25; 56(6):385-392. PubMed ID: 34154313
    [Abstract] [Full Text] [Related]

  • 3. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, Bordi G, Vitagliano A, Saccardi C, Skof E.
    Radiol Oncol; 2018 Sep 11; 52(3):307-319. PubMed ID: 30210049
    [Abstract] [Full Text] [Related]

  • 4. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.
    Gynecol Oncol; 2017 Feb 11; 144(2):266-273. PubMed ID: 27916269
    [Abstract] [Full Text] [Related]

  • 5. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS, Zhang Y, Zhang P, Zhu T, Aoki D, Yu A, Chen X, Wang X, Zhu D, Zhang W, Jia H, Shi T, Gao W, Yin S, Feng Y, Xiang L, Okamoto A, Zang R.
    J Gynecol Oncol; 2020 Sep 11; 31(5):e86. PubMed ID: 32808504
    [Abstract] [Full Text] [Related]

  • 6. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Davidson BA, Broadwater G, Crim A, Boccacio R, Bixel K, Backes F, Previs RA, Salinaro J, Salani R, Moore K, Secord AA.
    Gynecol Oncol; 2019 Mar 11; 152(3):554-559. PubMed ID: 30558972
    [Abstract] [Full Text] [Related]

  • 7. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M, Chambers LM, Costales AB, Chichura A, Gruner M, Horowitz MP, Rose PG, Yao M, Debernardo R, Michener C.
    Gynecol Oncol; 2021 Jan 11; 160(1):45-50. PubMed ID: 33067001
    [Abstract] [Full Text] [Related]

  • 8. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
    Psomiadou V, Prodromidou A, Fotiou A, Lekka S, Iavazzo C.
    J Robot Surg; 2021 Apr 11; 15(2):155-163. PubMed ID: 33037532
    [Abstract] [Full Text] [Related]

  • 9. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
    Thomas QD, Boussere A, Classe JM, Pomel C, Costaz H, Rodrigues M, Ray-Coquard I, Gladieff L, Rouzier R, Rouge TM, Gouy S, Barranger E, Sabatier R, Floquet A, Marchal F, Guillemet C, Polivka V, Martin AL, Colombo PE, Fiteni F.
    Gynecol Oncol; 2022 Oct 11; 167(1):11-21. PubMed ID: 35970603
    [Abstract] [Full Text] [Related]

  • 10. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA, Rychlik A, Cabarrou B, Spagnolo E, Guyon F, Pérez-Benavente A, Gil-Moreno A, Siegrist J, Querleu D, Mery E, Gladieff L, Hernández A, Ferron G, Martinez A.
    Gynecol Oncol; 2020 Sep 11; 158(3):614-621. PubMed ID: 32709536
    [Abstract] [Full Text] [Related]

  • 11. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J, Drury L, Crane EK, Anderson WE, Tait DL, Higgins RV, Naumann RW.
    J Minim Invasive Gynecol; 2019 Sep 11; 26(5):902-909. PubMed ID: 30240899
    [Abstract] [Full Text] [Related]

  • 12. Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study.
    Liu X, Zhao Y, Jiao X, Yu Y, Li R, Zeng S, Chi J, Ma G, Huo Y, Li M, Peng Z, Liu J, Zhou Q, Zou D, Wang L, Li Q, Wang J, Yao S, Chen Y, Ma D, Hu T, Gao Q.
    J Ovarian Res; 2023 Jun 27; 16(1):121. PubMed ID: 37370087
    [Abstract] [Full Text] [Related]

  • 13. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Sia TY, Manning-Geist BL, Ehmann S, Lavery JA, Luardo C, Praiss A, Iasonos A, Sonoda Y, Grisham RN, Liu YL, Broach V, Zivanovic O, Long Roche K, Gardner GJ, Chi DS.
    Gynecol Oncol; 2023 Sep 27; 176():69-75. PubMed ID: 37454565
    [Abstract] [Full Text] [Related]

  • 14. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R.
    Cochrane Database Syst Rev; 2022 Sep 26; 9(9):CD015048. PubMed ID: 36161421
    [Abstract] [Full Text] [Related]

  • 15. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E, Katsaros D, Maggiorotto F, Aglietta M, Vaira M, De Simone M, Mittica G, Giannone G, Robella M, Genta S, Lucchino F, Marocco F, Borella F, Valabrega G, Ponzone R.
    J Ovarian Res; 2018 May 30; 11(1):42. PubMed ID: 29843747
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
    Persenaire C, Pyrzak A, Barber EL.
    J Minim Invasive Gynecol; 2022 Mar 30; 29(3):375-384. PubMed ID: 34648931
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.
    Gao Y, Li Y, Zhang C, Han J, Liang H, Zhang K, Guo H.
    J Ovarian Res; 2019 Sep 13; 12(1):85. PubMed ID: 31519183
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.